En route to long-term control?
Professor Thaçi gives a detailed history of the progress in scientific understanding that has led to the current diverse range of targeted therapies for psoriasis. He presents the data that shows that IL-23 inhibition is more appropriate for long-term disease control and asks whether remission is possible?
The Psoriasis Management, Psoriasis Treatment and Psoriasis Guidelines content has been developed by EPG Health for Medthority. This content has been developed independently of the sponsor Almirall S.A, who have had no editorial input into the content. EPG Health received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.
The Expert Opinion and PsoMOT content has been developed by EPG Health for Medthority in collaboration with the sponsor Almirall S.A., utilising content from their Almirall funded symposium at EADV 2021 and PsoMOT meeting in November 2019.